Impact of neoadjuvant chemotherapy on breast reconstruction
β Scribed by Yue-Yung Hu; Christine M. Weeks; Haejin In; Christopher M. Dodgion; Mehra Golshan; Yoon S. Chun; Michael J. Hassett; Katherine A. Corso; Xiangmei Gu; Stuart R. Lipsitz; Caprice C. Greenberg
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 146 KB
- Volume
- 117
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Neoadjuvant chemotherapy in breast cancer was developed in the 1970s and is now used in patients with locally advanced or early resectable breast cancer. Early administration of systemic chemotherapy before local treatment in locally advanced breast cancer and early resectable breast cancer is inten
## Abstract ## BACKGROUND The majority of patients with breast carcinoma receive chemotherapy as a component of multimodality treatment. Over the past decade, it has become increasingly more common to deliver chemotherapy first, but this has raised new questions within all disciplines of cancer ma
## Abstract ## BACKGROUND. Reconstruction is rarely incorporated into the decisionβmaking process for surgical breast cancer treatment. We examined the importance of knowing about reconstruction to patients' surgical decisionβmaking for breast cancer. ## METHODS. We surveyed women aged β€79 years
## Abstract ## Background The aim of this study was to compare the outcomes of skin-sparing mastectomy (SSM) with immediate myocutaneous flap reconstruction and partial mastectomy with latissimus dorsi miniflap reconstruction (LDMF) for breast cancer. ## Methods Some 106 disease-free patients (5